Mural Oncology (NASDAQ:MURA) Receives Hold Rating from Jones Trading

Mural Oncology (NASDAQ:MURA)‘s stock had its “hold” rating reissued by equities research analysts at Jones Trading in a research note issued on Tuesday,Benzinga reports.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Mural Oncology in a research report on Wednesday, March 12th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Mural Oncology has a consensus rating of “Buy” and an average price target of $16.00.

Mural Oncology Stock Performance

MURA stock opened at $3.83 on Tuesday. The stock has a market capitalization of $65.98 million, a P/E ratio of -0.42 and a beta of 3.66. Mural Oncology has a one year low of $2.87 and a one year high of $5.12. The company has a 50 day moving average price of $3.91 and a two-hundred day moving average price of $3.63.

Mural Oncology (NASDAQ:MURA) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($2.01) EPS for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same period in the previous year, the business earned ($3.57) EPS. Research analysts forecast that Mural Oncology will post -7.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Mural Oncology

A number of large investors have recently added to or reduced their stakes in the company. Commerce Bank purchased a new stake in shares of Mural Oncology during the third quarter worth about $39,000. FMR LLC increased its holdings in Mural Oncology by 124.7% in the third quarter. FMR LLC now owns 20,580 shares of the company’s stock valued at $64,000 after buying an additional 11,423 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Mural Oncology during the 3rd quarter valued at approximately $340,000. Geode Capital Management LLC lifted its stake in Mural Oncology by 2.6% during the third quarter. Geode Capital Management LLC now owns 190,056 shares of the company’s stock worth $595,000 after purchasing an additional 4,731 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Mural Oncology in the fourth quarter worth $181,000. 80.21% of the stock is owned by institutional investors and hedge funds.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.